PF-04929113 (SNX-5422) is originally developed by Pfizer and Serenex, Inc., and the phase I clinical trials for PF-04929113 (SNX-5422) has been completed in the treatment of solid tumors.

June 21, 2017

prudect name : PF-04929113 (SNX-5422) is originally developed by Pfizer and Serenex, Inc., and the phase I clinical trials for PF-04929113 (SNX-5422) has been completed in the treatment of solid tumors.
PF-04929113

Synonyms: SNX-5422CAS NO: 908115-27-5Molecular Formula: C₂₅H₃₀F₃N₅O₄Molecular Weight: 521.53Purity: 98% minSolubility: In DMSOStorage: -20°C

web site: www.medchemexpress.com